Table 4.
Clinical characteristics and maternal and fetal outcomes in pregnant women with APL treated with ATO in this study and literature.
| Case no. | Age, years | APL risk score | Gestational age at diagnosis, weeks | Treatment | Dose of ATO received | Fetal exposure in utero to ATO, days | Therapy outcome | Gestational age at delivery/abortion, weeks | Delivery method | Fetal outcome | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases in this Study |
1 | 29 | Intermediate | 17+5 | ATO monotherapy | 0.17 mg/kg/day (10 mg/day) | 28 | CR | 23+4 | TA (polyhydramnios) | Aborted fetus |
| 2 | 31 | Low | 20 | ATO monotherapy | 0.16 mg/kg/day (10 mg/day) | 28 | CR | 24 | TA | Aborted fetus | |
| 3 | 34 | Low | 37 | ATO monotherapy | 0.16 mg/kg/day (10 mg/day) | 15 | CR | 39+1 | Vaginal | Healthy infant | |
| Cases in literature |
1 (18) | 30 | \ | 2 | ATO+ATRA+DNR | \ | 57 | CR | 10+1 | TA | Aborted fetus |
| 2 (19) | 25 | Low/Intermediate | 5 | ATO+ATRA+DNR | \ | 28 | CR | 9 | SA | Aborted fetus | |
| 3 (19) | 28 | Low/Intermediate | 5 | ATO+ATRA+IDA | \ | 14 | CR | 7 | TA | Aborted fetus | |
| 4 (20) | 25 | High | 8 | ATO+ATRA+DNR | \ | 21 | CR | 11 | TA | Aborted fetus | |
| 5 (21) | 32 | Intermediate | 9 | ATO+ATRA | 10 mg/day | 21 | CR | 12 | TA | Aborted fetus | |
| 6 (22) | 25 | Low | 9+5 | ATO+ATRA | 10 mg/day | 23 | CR | 13+1 | TA | Aborted fetus | |
| 7 (23) | 26 | High | 10 | ATO+ATRA+DNR | \ | 21 | CR | 13 | TA | Aborted fetus | |
| 8 (19) | 26 | Low/Intermediate | 10 | ATO+ATRA | \ | 35 | CR | 15 | TA | Aborted fetus | |
| 9 (24) | 25 | Low | 11+3 | ATO+ATRA | 0.15 mg/kg | 14 | CR | 14+1 | TA | Aborted fetus | |
| 10 (18) | 31 | \ | 12 | ATO+ATRA+DNR | \ | 80 | CR | 23+3 | TA | Aborted fetus | |
| 11 (25) | 33 | Low | 12+4 | ATO+ATRA+IDA | 10 mg/day | 35 | CR | 17+4 | TA | Aborted fetus | |
| 12 (18) | 23 | \ | 12+4 | ATO+ATRA+DNR | \ | 72 | CR | 23+6 | TA | Aborted fetus | |
| 13 (19) | 27 | Low/Intermediate | 13 | ATO+ATRA+DNR | \ | 28 | CR | 17 | TA | Aborted fetus | |
| 14 (26) | 22 | Intermediate | 14 | ATO+ATRA | 0.15 mg/kg/day (10 mg/day) | 93 | CR | 40+6 | Vaginal | Healthy infant | |
| 15 (27) | 28 | Intermediate | 23+4 | ATO+ATRA | \ | 25 | CR | 28 | TA | Aborted fetus | |
| 16 (24) | 28 | Intermediate | 24+4 | ATO+ATRA | 0.15 mg/kg | 23 | CR | 29+4 | TA | Aborted fetus | |
| 17 (22) | 28 | Intermediate | 24+5 | ATO+ATRA | 10 mg/day | 30 | CR | 29 | TA | Aborted fetus | |
| 18 (28) | 23 | High | 27 | ATO+ATRA +IDA | 0.15 mg/kg | 35 | CR | 32 | Cesarean | Healthy infant | |
| 19 (29) | 29 | \ | 27 | ATO + ATRA + DNR | \ | \ | CR | \ | TA | Aborted fetus | |
| 20 (30) | 31 | Intermediate | 27 | ATO monotherapy | 10 mg/day | 10 | CR | 29 | ID+TA | Aborted fetus | |
| 21 (30) | 30 | Intermediate | 27+1 | ATO+ATRA+HHRT | 10 mg/day | 70 | CR | 37 | Cesarean | Healthy infant | |
| 22 (18) | 33 | \ | 28 | ATO+ATRA | \ | 87 | CR | 40+3 | Vaginal | Healthy infant | |
| 23 (31) | 27 | Intermediate | 31+ | ATO+ATRA+DNR | 10 mg/day | 14 | CR | 33+ | Cesarean (fetal distress) | Healthy infant | |
| 24 (32) | 37 | \ | 32 | ATO+ATRA | \ | 20 | CR | \ | Cesarean | Healthy infant | |
| 25 (33) | 28 | Intermediate | 34+4 | ATO+ATRA+DNR | 10 mg/day | 16 | CR | 37+5 | Cesarean | Healthy infant | |
| 26 (34) | 23 | Low | 35 | ATO+ATRA | 0.15 mg/kg | 21 | CR | 38 | Vaginal | Healthy infant | |
| 27 (35) | 27 | Low | 36 | ATO+ATRA | 10 mg/day | 6 | CR | 38 | Cesarean | Healthy infant | |
| 28 (29) | 30 | \ | 36 | ATO+ATRA+DNR | \ | \ | CR | \ | Cesarean | Healthy infant |
APL, acute promyelocytic leukemia; CR, complete remission; ATO, arsenic trioxide; ATRA, all-trans-retinoic acid; TA, therapeutic abortion; SA, spontaneous abortion; DNR, daunorubicin; IDA, idarubicin; HHRT, homoharringtonine; ID, Intrauterine death.